Intensity Therapeutics (INTS) Q4 2025 earnings summary

Executive summary

• Raised over $20 million in gross proceeds in 2025, ending the year with $11.9 million in cash and cash equivalents, providing a cash runway into Q2 2027.

• Published IT-01 Study results in eBioMedicine, showing promising disease control and survival data for INT230-6 in refractory metastatic cancer.

• Reported favorable efficacy and safety for INT230-6 in triple negative breast cancer patients in the INVINCIBLE-4 Study.

Financial highlights

• Research and development expenses were $6.8 million for 2025, down from $10.5 million in 2024, mainly due to lower clinical trial and manufacturing costs.

• General and administrative expenses were $5.2 million for 2025, down from $6.1 million in 2024, reflecting cost efficiencies.

• Net loss for 2025 was $11.6 million, compared to $16.3 million in 2024.

• Cash and cash equivalents totaled $11.9 million as of December 31, 2025.

Outlook and guidance

• Plans to resume patient enrollment and site activations in paused clinical studies during 2026, contingent on securing additional funding.

• Cash runway is expected to last into the second quarter of 2027.